ALCMI Board Member with SC Ties

Harvey I. Pass, MD is Professor of Cardiothoracic Surgery and Surgery, and the first Division Chief of Thoracic Surgery/ Thoracic Oncology at NYU School of Medicine. He joined NYU Medical Center in 2005 to lead the Division of Thoracic Surgery and Thoracic Oncology. His previous positions include Chief, Thoracic Oncology at the Karmanos Cancer Institute, and Head of the Thoracic Oncology Section of the National Cancer Institute (NCI) for the National Institutes of Health.

Dr. Pass received his B.A. from Johns Hopkins University and his M.D. from Duke University. He completed his surgical residency at Duke and University of Mississippi. He completed his residency in Cardiothoracic Surgery at the Medical University of South Carolina. Dr. Pass also completed a fellowship in Thoracic Oncology at NCI.

The Addario Lung Cancer Medical Institute (ALCMI)
is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for Lung Cancer patients.

The State reports: Senate approves 50-cent cig tax increase

House vote to override expected veto to be close
By JOHN O'CONNOR and RODDIE BURRIS - joconnor@thestate.com rburris@thestate.com

NASCAR vice president of corporate communications and former Darlington president Jim Hunter is a lung cancer warrior...

"Jim Hunter is back doing to the two things he loves the most — being at the race track and playing golf.

That wasn’t the case seven months ago when the former Darlington Raceway president was diagnosed with small-cell lung cancer in his right lung Oct. 31."

Read more.

from The State back in January: Love, faith, provide armor in cancer fight for Maddens

Love, faith, provide armor in cancer fight for Maddens

In memory of Mr. Herman Madden.

Abraxis' Abraxane meets lung cancer study goal

Abraxis BioScience's Abraxane meets key treatment goal in lung cancer study

LOS ANGELES (AP) -- Abraxis BioScience Inc. said Wednesday its drug Abraxane met key treatment goals in a late-stage lung cancer study.

The company said Abraxane with Taxol, in combination with chemotherapy, improved the overall response rate of patients in the 1,052 patient study. The study focused on patients receiving initial treatment for lung cancer and compared the Abraxane combination with patients only receiving Taxol and another chemotherapy, carboplatin.

Abraxane is already approved as a breast cancer treatment. The company expects to ask for FDA approval as a lung cancer treatment in 2011.

Shares of Abraxis jumped $12.77, or 32.1 percent, to $52.62 in morning trading. The stock has traded between $24.52 and $57.60 over the last 52 weeks